Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...
BioPharma Dive10d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
MarketWatch10d
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute ...
MedPage Today on MSN10d
Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy
A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
BioSpace9d
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
GEN - Genetic Engineering and Biotechnology News5d
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Reuters10d
Sarepta says teen died after its gene therapy treatment
Patient was a 16-year-old teen, who underwent treatment in Dec First death reported after Elevidys treatment Liver injury a known risk with gene therapies March 18 (Reuters) - Sarepta Therapeutics ...
Newsday10d
Patient dies following muscular dystrophy gene therapy, Sarepta reports
WASHINGTON — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting more than 25%.
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst Downgrade
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...
Yahoo Finance10d
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment ...
Seeking Alpha9d
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics stock dropped over 20% after a patient treated with Elevidys for DMD died from acute liver failure, raising safety concerns. Despite the incident, Sarepta maintains that the ...